Skip to main content
Clinical Trials/NCT04950634
NCT04950634
Completed
Not Applicable

Sexual Dimorphism in the Prevalence and Progression of Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal1 site in 1 country320 target enrollmentSeptember 1, 2018
Conditionstype1diabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
type1diabetes
Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Enrollment
320
Locations
1
Primary Endpoint
To address sexual dimorphism in subclinical atherosclerosis in patients with T1D.
Status
Completed
Last Updated
8 months ago

Overview

Brief Summary

Sex might interact with cardioautonomic neuropathy (CAN) in the development of macrovascular disease in patients with type 1 diabetes (T1D). The regulation of the autonomic system shows sexual dimorphism, and may contribute to the cardiovascular risk overload in women with T1D.

The aims of this project are:

A.1) Determining the prevalence of CAN and subclinical atherosclerosis in a large cohort of consecutive patients with T1D as a function of sex (cross-sectional study).

A.2.) Addressing the progression of CAN and subclinical atherosclerosis in patients with T1D as a function of sex (longitudinal prospective study).

A.3.) Investigating the influence of sex steroids and circulating biomarkers in the development and progression of CAN and subclinical atherosclerosis.

Research designs:

A cross-sectional design/prevalence screening study determining the prevalence of CAN as a function of sex in 320 consecutive individuals with DM1.

A longitudinal prospective study: the cohort of prevalence screening study will be prospectively followed, and the assessment of cardiovascular autonomic function and subclinical atherosclerosis will be repeated over time.

Registry
clinicaltrials.gov
Start Date
September 1, 2018
End Date
August 1, 2025
Last Updated
8 months ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of type 1 diabetes mellitus, as defined by ADA criteria

Exclusion Criteria

  • Renal transplantation or renal replacement therapy;
  • prior diagnosis of macrovascular disease (CHD, cerebrovascular disease, carotid disease, PAD, or atherosclerotic aortic aneurism);
  • ongoing pregnancy;
  • diagnosis of types of diabetes mellitus other than type 1;
  • diagnosis of types of neuropathy other than diabetic neuropathy.

Outcomes

Primary Outcomes

To address sexual dimorphism in subclinical atherosclerosis in patients with T1D.

Time Frame: Two years

Mean carotid intima-media thickness (mm)

To address sexual dimorphism in the prevalence of CAN in patients with T1D.

Time Frame: Two years

Heart rate responses (bpm) to active standing and Ewing and Clarke tests.

To assess the role of sex on the progression of cardiovascular dysautonomy in patients with T1D.

Time Frame: Four years

Heart rate responses (bpm) to active standing and Ewing and Clarke tests.

To assess the role of sex on the progression of subclinical atherosclerosis in patients with T1D.

Time Frame: Four years

Mean carotid intima-media thickness (mm)

Secondary Outcomes

  • To identify the influence of sex steroids on the evolution of cardiac autonomic dysfunction.(Four years)
  • To identify novel circulating markers of subclinical atherosclerosis(Four years)
  • To identify the influence of sex steroids on the evolution of subclinical atherosclerosis(Four years)
  • To identify novel circulating markers of CAN(Four years)

Study Sites (1)

Loading locations...

Similar Trials